ABHD17A

Across TCGA pan-cancer cohorts, ABHD17A RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated ABHD17A data layer compared with 3 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ABHD17A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABHD17A expression acts as an unfavorable survival marker, although some lineages such as UCEC and PAAD show a favorable association.

ACC, UCEC, and PAAD are the cancer types where ABHD17A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.223	0.687	<.001	118	view →
UCEC	OS	Median	All	0.808	0.574	<.001	68	view →
PAAD	OS	Median	All	0.515	0.274	<.001	54	view →
LGG	DFS	Median	All	0.646	0.814	<.001	37	view →
KICH	OS	Median	III,IV	0.347	0.942	.001	30	view →
PRAD	DFS	Median	All	0.686	0.894	<.001	28	view →
HNSC	OS	Tertile	II,III,IV	0.820	0.687	.001	22	view →
UCS	OS	Tertile	IV	0.241	1.000	.036	18	view →
COAD	DFS	Tertile	IV	0.266	0.780	.021	16	view →
LIHC	OS	Quartile	III,IV	0.139	0.648	<.001	15	view →
LUSC	OS	Median	II,III,IV	0.709	0.363	.005	15	view →
CHOL	OS	Median	All	0.842	0.234	.037	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

ABHD17A–ACC (DFS)

Open the ACC breakdown →